Member Info for DinoMustafic

Net income went really up, 2 million, but way up, and they're expanding more to Nordic region.. http://bit.ly/2lU5hZ9

“The rapid roll-out of our nationwide ambulatory clinic model, and our significant new participation in the Georgian pharmaceuticals market will continue to create further business development and cost efficiency opportunities over the next few years,” said the group’s CEO Nikoloz Gamkrelidze. http://bit.ly/2kIBbrw

Highligh: expanding the distribution of angina prevention medicine, Imdur. http://bit.ly/2koOZLN

They said it could increase the revenue from top 20 customers by 20% with this deal http://www.pharmaceuticaldaily.com/horizon-discovery-expands-deal-with-its-largest-single-customer/

Hikma won exclusive licensing and distribution agreement for pulmonary disease drug http://bit.ly/2knuZV4

Oxford BioDynamics appoints Dr Claudio Carini as an advisor . he worked for pfizer... what's this could mean something, a valuable addition. http://www.pharmaceuticaldaily.com/oxford-biodynamics-welcomes-dr-claudio-carini-to-its-scientific-advisory-panel/

Evgen Pharma has signed a services agreement with APTrans for developing its anti-stress drug SFX-01, currently in phase II clinical testing. http://bit.ly/2l68Wqf

£7 million for staying positive about prospects, http://bit.ly/2kPJHpn

leaving non-executive who pulled the ropes during the first year in public says "future is bright", but he's focusing on other business http://bit.ly/2kVKXth

...extensive commercial experience, particularly in the United States... http://www.pharmaceuticaldaily.com/allergy-therapeutics-appoints-abbotts-licensing-and-acquisitions-vice-president-to-its-board/

They will soon begin the final testing for this candidate, and the potential market for the drug is 1 billion yearly. No current cure, this'll be the only http://www.pharmaceuticaldaily.com/amryt-secures-japanese-patent-for-its-butterfly-children-drug-candidate-episalvan-soon-kicks-off-phase-iii-study/

AstraZeneca’s hopes to launch several cancer, respiratory and metabolic diseases drugs, as it expects to see the effects of its long-term growth. The drugmaker nears the end of its patent-expiry period as it expects to bring new medicines to the stores. http://www.pharmaceuticaldaily.com/astrazenecas-sales-drop-expects-to-launch-several-new-drugs-this-year/

The results of the study expected in 2018, but who knows... http://www.pharmaceuticaldaily.com/dbv-technologies-completes-p-ii-study-of-milk-induced-eoe-treatment/

"AstraZeneca expects a single-digit percentage decline in revenue for the 2017." http://www.pharmaceuticaldaily.com/astrazenecas-sales-drop-expects-to-launch-several-new-drugs-this-year/

http://www.pharmaceuticaldaily.com/european-commission-oks-novartiss-tuberous-sclerosis-complex-drug/

Shield Therapeutics has appointed Capita Registrars Limited as company secretary, after Richard Jones has officially resigned. http://www.pharmaceuticaldaily.com/short-shields-secretary-officially-resigns/

This active rheumatoid arthritis could be approved soon in EU http://www.pharmaceuticaldaily.com/chmp-recommends-pfizers-rheumatoid-arthritis-drug-for-european-approval/

If FDA approves application, Realm will initiate a Phase 2a proof-of-concept trial http://www.pharmaceuticaldaily.com/realm-therapeutics-asks-fdas-approval-for-its-first-ind-for-atopic-dermatitis-treatment/

Tregoning will lead its External Affairs organization which includes Market Access, Public Affairs, Government Affairs, Corporate Communications, Global Policy, and Corporate Social Responsibility. http://www.pharmaceuticaldaily.com/sanofi-welcomes-kathleen-tregoning-to-its-executive-committee/

It gets exclusivity rights for 6 months in US Symbicort is currently approved in the US to treat asthma in patients 12 years and older and for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults. http://www.pharmaceuticaldaily.com/astrazenecas-symbicort-for-asthma-available-for-6-12-y-o-children-in-usa-fda-issues-exclusivity-rights/